Safety and Tolerability Profile Gastrointestinal Adverse Effects GI side effects are the dominant tolerability issue, consistent with all GLP-1-based therapies
46 In studies evaluating the efficacy and safety of GLP-1 RAs, nausea emerged as the most frequently reported GI symptom, generally following a dose-dependent pattern, appearing during the first weeks of therapy, and decreasing as tolerance developed
Rothmeier J., ZFP Sdwrttemberg Weissenau, Department of Neurology
How long does it take for Saxenda to work
Although high peripheral exposure may be required to obtain the fractional central exposure necessary to illicit a pharmacologic response, insufficient selectivity between MC1R and MC4R activity can lead to peripheral activation of MC1R (142, 143)
Mechanisms of fibrogenesis in liver cirrhosis: The molecular aspects of epithelial-mesenchymal transition